Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report) saw a significant decline in short interest in August. As of August 14th, there was short interest totaling 1 shares, a decline of 99.9% from the July 30th total of 884 shares. Based on an average daily volume of 143 shares, the days-to-cover ratio is presently 0.0 days.
Drugs Made in America Acquisition Stock Performance
NASDAQ:DMAAU opened at $10.79 on Thursday. The business’s fifty day moving average is $10.79 and its 200 day moving average is $10.70. Drugs Made in America Acquisition has a 52-week low of $10.30 and a 52-week high of $12.50.
About Drugs Made in America Acquisition
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
Featured Stories
- Five stocks we like better than Drugs Made in America Acquisition
- NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
- Alphabet Is Building a Base—Could a Breakout Be Next?
- When Unusual Volume Isn’t Noise: 3 Small-Caps Sending Signals
- Is Quantinuum Emerging as a Leader in the Quantum Race?
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
